TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from MetaVia ( (MTVA) ).
On August 4, 2025, MetaVia Inc. announced a research collaboration with Syntekabio, Inc. to explore additional indications for DA-1241, a novel oral G-Protein-Coupled Receptor 119 (GPR119) agonist. This partnership aims to leverage Syntekabio’s AI-driven DeepMatcher® platform to optimize DA-1241’s therapeutic profile and identify new disease targets. This collaboration follows positive results from a Phase 2a study of DA-1241, which showed favorable safety and efficacy in MASH patients. The initiative is expected to enhance MetaVia’s industry positioning by expanding the drug’s therapeutic potential, potentially addressing a range of unmet medical needs.
The most recent analyst rating on (MTVA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on MetaVia stock, see the MTVA Stock Forecast page.
Spark’s Take on MTVA Stock
According to Spark, TipRanks’ AI Analyst, MTVA is a Underperform.
MetaVia’s overall stock score is heavily impacted by its poor financial performance, characterized by persistent losses and no revenue generation. The technical analysis indicates weak market momentum, and negative valuation metrics highlight the stock’s high-risk profile. Although recent positive trial results provide some potential for future growth, significant strategic changes are necessary for the company to achieve financial stability and investor confidence.
To see Spark’s full report on MTVA stock, click here.
More about MetaVia
MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. The company is developing DA-1726 for obesity treatment and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
Average Trading Volume: 263,020
Technical Sentiment Signal: Sell
Current Market Cap: $11.93M
Learn more about MTVA stock on TipRanks’ Stock Analysis page.